---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-028601"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T01:51:18.509969+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lyra Therapeutics Q2 net loss $14.5M; cash $120.7M; CMO appointed; Phase 3 enrollment ongoing

## Summary
- Net loss $14.5M for Q2 2022 vs $11.0M in Q2 2021; R&D expenses $10.8M.
- Cash and equivalents $120.7M as of June 30, 2022; cash runway to mid-2024.
- Closed private placement of ~$96.3M net proceeds in April 2022.
- Appointed Richard Nieman, MD as Chief Medical Officer.
- ENLIGHTEN Phase 3 program enrolling; ENLIGHTEN II first patient expected Q3; enrollment complete mid-2023.

## SEC filing metadata
- accession: 0001564590-22-028601
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000156459022028601/0001564590-22-028601-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000156459022028601/lyra-8k_20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-028601
- JSON: https://secwatch.observer/filing/0001564590-22-028601.json
- Plain text: https://secwatch.observer/filing/0001564590-22-028601.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.